IPK renders access to our innovative drug screening expertise and technologies in biosafety level-2/-3 laboratories providing domestic and international partners the opportunity to advance their own drug development programs. The highly experienced professionals of IPK provide various services through all stages of the screening process including biochemical, cell-based, or custom assay design and adaptation, combinatorial screening, proof-of-concept screening, small to large scale screenings, dose-response studies, as well as chemical analysis and molecular modeling.
Over the fifteen years since our founding, IPK has established itself an international reputation as a go-to partner for pre-clinical screening in infectious diseases. In this context, we are sought by many partners from academia, public/private research institutes, NGOs, and industry.
Specifically, this was exemplified in 2020 and 2021 as IPK expedited fee-for-service support for COVID-19 related screening requests for over 120 organizations that approached us for support and partnership. These activities included the evaluation of antiviral efficacy for candidate compounds and antibodies against SARS-CoV-2 using our already developed cell- based assays. Indeed, our own studies revealed potent candidates now undergoing clinical trials by partners.
Importantly, as a member of Korea’s pan-governmental COVID-19 treatment and vaccine R&D supporting group, IPK has been helping domestic companies with in vitro drug efficacy evaluation. We are also operating a flagship laboratory of the National Institute of Infectious Diseases for drug antiviral efficacy evaluation and participating in the Consortium of Infectious Disease Research initiated to respond to the national crisis of (re)emerging infectious diseases.
IPK has been active in collaborating with major domestic and foreign pharmaceutical and bio venture companies, covering various research fields. In particular, we have been carrying out screening to accelerate drug discovery for diseases such as Leishmaniasis, Chagas disease, and COVID-19 by means of our long-term cooperation with DNDi.
We welcome researchers and industry partners interested in exploring opportunities for screening services, scientific partnerships, and other commercialization initiatives.